About Altor Bioscience
Altor Bioscience is a Healthcare company based in United States founded in 2002 by Hing Wong, and was acquired by NantHealth in June 2017. Immunotherapeutics for cancer and infectious diseases are developed. Altor Bioscience has raised $92.71 million across 30 funding rounds from investors including NantHealth, HHS and National Cancer Institute. Its chief executive, as recorded, is Hing Wong. Altor Bioscience offers products and services including ANKTIVA, NK-92 Cell Line, and rBCG. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Vaccine. Its legal entity is ImmunityBio, Inc. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
Altor Bioscience was founded in 2002 in the United States. Focus is placed on the biotechnology sector, where cell and immunotherapy products are developed for treating cancer and infectious diseases. The product pipeline features Anktiva, targeted at bladder and lung cancer. Operations center on advancing these therapeutic options through research and development efforts.
- Headquarters United States
- Founders Hing Wong
- Stage Acquired
- SectorsHealthcare
- Website altorbioscience.com
- Social LinkedIn X Facebook
- Acquired by NantHealth (Jun 2017)
- Legal Name Immunitybio, Inc.
- Total Equity Funding$92.71M (USD)
in 30 rounds
- Latest Funding Round$4.19M (USD), Grant
Sep 2018
- InvestorsNantHealth
& 3 more
- Acquired byNantHealth
(Jun 2017)
Products & Services of Altor Bioscience
Altor Bioscience offers a comprehensive portfolio of products and services, including ANKTIVA, NK-92 Cell Line, and rBCG.
Enhances immune system to treat bladder and other cancers.
Provides natural killer cells for bioanalytical testing in trials.
Recombinant BCG for addressing BCG shortages in cancer treatment.
Funding Insights of Altor Bioscience
Altor Bioscience has successfully raised a total of $92.71M across 30 strategic funding rounds. The most recent funding activity was a Grant round of $4.19 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.71M
- Total Rounds 30
- Last Round Grant — $4.19M
- First Round $2.97M
(Jul 2002)
- Investors Count 3
Latest 10 of 30 funding rounds of Altor Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $4.19M | Grant | – | – | |
| Mar 2017 | $30.33M | Series G | – | – | – |
| Jul 2016 | $20M | Series F | – | – | – |
| Jun 2015 | $10.72M | Series E | – | – | – |
| Aug 2014 | $1.2M | Grant | – | – | |
| Feb 2013 | $5.5M | Series D | – | – | – |
| Sep 2012 | $257,303 | Grant | – | – | |
| Jul 2012 | $11.3M | Series D | – | – | – |
| Jul 2012 | $231,853 | Grant | – | – | |
| Jul 2012 | $1.12M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Altor Bioscience
Altor Bioscience has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NantHealth, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical investment financing and active management services. | sanderling.com | |||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Bioinformatics platforms are provided for cancer treatment identification. | 2007 | nanthealth.com | El Segundo, United States |
Investor details for Altor Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Altor Bioscience
46 people are tracked at Altor Bioscience (23 in leadership, 6 in board & advisors, 17 in team).
| Name | Role | Group |
|---|---|---|
Hing Wong | Founder & CEO | Leadership |
Rich Adcock | President & CEO | Leadership |
David Sachs | CFO | Leadership |
Leonard S. Sender | COO | Leadership |
Sarah Singleton | Chief Communications Officer | Leadership |
Barry Simon | Chief Corporate Affairs Officer | Leadership |
Percy van Rijn | Head Of Commercial Operations | Leadership |
Vivian Kim | Director, Clinical, Preclinical & Diagnostic Quality Assurance | Leadership |
Jennifer Jacobs | Director - Assistant Controller | Leadership |
Paula Bradshaw | Vice President, Clinical Business Operations | Leadership |
Jon van Lew | Director, Engineering | Leadership |
Lucinda Y. | Sr Director, Fp&a | Leadership |
Maia L. Green | Senior Director, Regulatory Toxicology | Leadership |
Steven Fridman | Director Cost Accounting | Leadership |
Camille Denoga | Senior Director Of Quality Systems & Compliance | Leadership |
Maureen Yue | Director Alliance Quality Management | Leadership |
Emily Arison | Senior Vice President Human Capital | Leadership |
Kristen Deleo | Executive Assistant To Cfo, General Counsel, SVP Of Human Resources | Leadership |
Charles Garlisi | Senior Vice President Regulatory Affairs | Leadership |
Hemanth Ramaprakash | Chief Of Staff & Strategic Business Development | Leadership |
26 more people are available in the full profile.
Complete people profiles for Altor Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Altor Bioscience
4 dated milestones of Altor Bioscience across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Altor Bioscience is founded.
- Funding First funding round of $3.0M.
- Exit Acquired by NantHealth.
- Funding Latest funding round, Grant, of $4.2M.
Competitors of Altor Bioscience
Altor Bioscience has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of Altor Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Altor Bioscience
Websites that share an audience with Altor Bioscience (altorbioscience.com).
Websites whose visitors overlap most with Altor Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alligatorbioscience.se | 100% | 9.9K | #1,706,633 | View details | |
| biosciencelabs.com | 100% | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Altor Bioscience (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Altor Bioscience
Altor Bioscience was founded in 2002.
Altor Bioscience is headquartered in United States.
Hing Wong is the CEO of Altor Bioscience, as recorded in our data. They have also founded this company.
Altor Bioscience is a funded company, having raised a total of $92.71M across 30 funding rounds to date. The company's 1st funding round was a Grant of $1.12M, raised on Jul 2002.
Altor Bioscience was founded in 2002 in the United States. Focus is placed on the biotechnology sector, where cell and immunotherapy products are developed for treating cancer and infectious diseases. The product pipeline features Anktiva, targeted at bladder and lung cancer. Operations center on advancing these therapeutic options through research and development efforts.
Altor Bioscience's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
Altor Bioscience offers ANKTIVA, NK-92 Cell Line, and rBCG.
Altor Bioscience has 4 investors. Key investors include NantHealth, HHS, National Cancer Institute, and Sanderling Ventures.
Altor Bioscience operates through Immunitybio, Inc..
Yes. Altor Bioscience was acquired by NantHealth in June 2017.